Jade Biosciences, Inc. (JBIO) - Net Assets
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) has net assets worth $296.46 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($319.43 Million) and total liabilities ($22.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check JBIO intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $296.46 Million |
| % of Total Assets | 92.81% |
| Annual Growth Rate | 157.47% |
| 5-Year Change | 92.86% |
| 10-Year Change | N/A |
| Growth Volatility | 2282.78 |
Jade Biosciences, Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Jade Biosciences, Inc.'s net assets have evolved over time, based on quarterly financial data. See JBIO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jade Biosciences, Inc. (2020–2025)
The table below shows the annual net assets of Jade Biosciences, Inc. from 2020 to 2025. For live valuation and market cap data, see JBIO company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $332.52 Million | +335.04% |
| 2024-12-31 | $76.43 Million | -30.17% |
| 2023-12-31 | $109.46 Million | -13.64% |
| 2022-12-31 | $126.74 Million | -26.49% |
| 2021-12-31 | $172.42 Million | +5762.56% |
| 2020-12-31 | $2.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jade Biosciences, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16098200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $129.00K | 0.04% |
| Other Components | $506.77 Million | 152.40% |
| Total Equity | $332.52 Million | 100.00% |
Jade Biosciences, Inc. Competitors by Market Cap
The table below lists competitors of Jade Biosciences, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cardinal Infrastructure Group Inc. Class A Common Stock
NASDAQ:CDNL
|
$998.48 Million |
|
Garcia Reguera S.A.
BA:REGE
|
$998.57 Million |
|
Huafa Industrial Co Ltd Zhuhai
SHG:600325
|
$998.76 Million |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
$998.97 Million |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
$998.39 Million |
|
Bonheur
OL:BONHR
|
$998.05 Million |
|
Altamir SCA
PA:LTA
|
$997.96 Million |
|
CW Enerji SA
IS:CWENE
|
$997.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jade Biosciences, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 76,434,000 to 332,518,000, a change of 256,084,000 (335.0%).
- Net loss of 127,410,000 reduced equity.
- New share issuances of 189,111,000 increased equity.
- Other comprehensive income increased equity by 24,000.
- Other factors increased equity by 194,359,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-127.41 Million | -38.32% |
| Share Issuances | $189.11 Million | +56.87% |
| Other Comprehensive Income | $24.00K | +0.01% |
| Other Changes | $194.36 Million | +58.45% |
| Total Change | $- | 335.04% |
Book Value vs Market Value Analysis
This analysis compares Jade Biosciences, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.99x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $4.22 | $16.82 | x |
| 2021-12-31 | $247.22 | $16.82 | x |
| 2022-12-31 | $181.27 | $16.82 | x |
| 2023-12-31 | $145.49 | $16.82 | x |
| 2024-12-31 | $93.60 | $16.82 | x |
| 2025-12-31 | $10.60 | $16.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jade Biosciences, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-38.32%) is above the historical average (-96.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -326.79% | 0.00% | 0.00x | 1.60x | $-9.91 Million |
| 2021 | -13.32% | 0.00% | 0.00x | 1.02x | $-40.20 Million |
| 2022 | -40.64% | 0.00% | 0.00x | 1.07x | $-64.19 Million |
| 2023 | -69.00% | 0.00% | 0.00x | 1.16x | $-86.47 Million |
| 2024 | -91.10% | 0.00% | 0.00x | 1.05x | $-77.27 Million |
| 2025 | -38.32% | 0.00% | 0.00x | 1.05x | $-160.66 Million |
Industry Comparison
This section compares Jade Biosciences, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $296.46 Million | -326.79% | 0.08x | $998.43 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more